MedTrace Logo

Radiolabeled Study of CC-122 in Healthy Subjects

NCT02234999 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-11-12

No results posted yet for this study

Summary

To evaluate the metabolism and excretion of \[14C\]-CC-122 in healthy male subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

CC-122

3mg \[14C\]-CC-122 will be administered as a single dose

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Edward O'Mara, MD · Celgene Corporation

Study Design

Allocation
NA
Purpose
OTHER
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-23
Primary Completion
2014-10-08
Completion
2014-10-08

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234999 on ClinicalTrials.gov